Saladax Licenses Alzheimer’s Diagnostic Tests to Siemens Healthineers

Tests can lead to early identification of Alzheimer’s Disease

Bethlehem, PA–(BUSINESS WIRE)–January 18, 2017– Saladax Biomedical, Inc., a privately held company focused on precision in-vitro diagnostic tests, announced today that it has signed an agreement to license diagnostic tests for Alzheimer’s disease (AD) to Siemens Healthineers. Saladax’s tests identify the amyloid beta 1-42 and tau biomarkers in cerebrospinal fluid (CSF) which are known and accepted biomarkers for AD.

Alzheimer’s Disease is currently the sixth leading cause of death in the U.S., affecting nearly 50 million patients worldwide, with 10 million new cases each year.  Presently, no disease-modifying therapeutics exist, and the available drugs provide limited alleviation of symptoms.  The use of tests to identify CSF biomarkers much sooner than previously available, will give clinicians the ability to more accurately identify AD and begin treatment sooner. Early detection of AD is also an important step in better understanding the disease.

The two biomarkers have been extensively studied for over 20 years, and are key indicators of the early stages of Alzheimer’s disease.  Currently, evidence of early AD can only be determined by PET (positron emission tomography) imaging equipment such as can be found with Siemen’s PETNET Solutions, or biomarkers such as Saladax’s amyloid beta 1-42 and tau tests.

“We are very excited to be working with Siemens Healthineers to bring these important assays to the market,” said Sal Salamone, Ph.D., CEO of Saladax Biomedical, Inc.  “Siemens is an ideal partner with a strong global position and high quality instrumentation.”

Under this non-exclusive agreement, Saladax will provide its proprietary raw materials, protocols, and intellectual property and Siemens will be responsible for the commercialization of both assays.

About Saladax Biomedical, Inc.
Saladax Biomedical is a leader in the development and deployment of high-quality diagnostic services and products to help physicians select and optimize the use of current and new pharmaceutical products, to improve treatment and positively impact the economics of care… because no two patients are alike.

Headquartered in Bethlehem, Pennsylvania, Saladax was founded in 2004 and is ISO 13485:2003 certified. For more information visit:

Company draws on capital connections

Stephanie Reisinger has worked in Harrisburg’s science and tech sector for over 16 years. In that time, she has experienced firsthand the benefits that the area can offer science and tech-focused companies.

The above article appeared in the October 28, 2016 edition of the Central Penn Business Journal to continue reading click here:


Often when one thinks of the life sciencesA cluster of scientific disciplines concerned with human life and health. Included are many branches of biology (e.g., molecular biology, cell biology) and chemistry (e.g., biochemistry), as well as some areas of genetics, physics and materials science, among others. industry, the larger metropolitan areas with sizeable research centers such as Boston and Philadelphia and Washington, DC are the first to come to mind.  However, …

This article was published in the 2016 Fall Edition of HRN HARRISBURG REGIONAL NEWS to continue reading click here: .  The article is on page 12.

Micro Interventional Devices, Inc. Receives FDA Market Clearance for Permaseal™

INDIGO Biosciences Raises $500 Thousand in Series B Funding

Micro Interventional Devices, Inc. Receives CE Mark Approval for Permaseal

Micro Interventional Devices, Inc. Receives CE Mark Approval for PermasealTM

Disruptive technology simplifies minimally invasive cardiovascular surgery. Newtown, PA – June 7, 2016 – Micro Interventional Devices, Inc.™ (MID), the world leader in minimally invasive and catheter-based compliant fixation technology announced today that it received CE Mark approval for the Company’s first product: Permaseal™ transapical access and closure device.  The Permaseal device allows surgeons to access and close the left-ventricle instantaneously, reliably and without suturing the myocardium. Permaseal is the world’s first device using compliant soft-tissue PolyCorTM anchor technology.

Permaseal was validated in the STASIS Clinical Study (Secure Transapical Access and Closure Study) conducted at five European Sites. Results indicated  that Permaseal shortened operating time and hospital stay, reduced adverse events including the need for transfusion and reduced 12-month mortality and stroke rates to 0%*. The technology provides a direct, safe and simple, access and closure site for emerging complex structural heart disease procedures including TAVR, TMVR, PFO, and other minimally invasive cardiac procedures.

“The CE Mark approval of Permaseal is a tremendous achievement for MID,” said Michael Whitman, MID’s Founder, President & CEO. “Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures. We are excited that this technology is now available to our European surgeons and their patients.”

“In the near future, PolyCor and MyoLastTM technologies will be utilized in a broad range of proprietary, catheter-based products, addressing unmet needs in tricuspid repair, mitral repair and mitral valve fixation,” added Whitman. “MID’s technology platform enables open-surgical procedures to be performed percutaneously.”

Permaseal is currently the only transapical access and closure device available for commercial use in the EU. FDA clearance to market Permaseal is pending.

*Data on file.

About Micro Interventional Devices, Inc. (MID):
MID is the world leader in compliant fixation technology addressing unmet needs in structural heart disease.

Company Contact:
Micro Interventional Devices, Inc.
Katherine Whitman
Product Director
215 600 1270

Here’s how to keep Pa’s medical innovation ecosystem healthy: Mel Billingsley

Researchers at Penn State’s Hershey Medical Center’s Division of Artificial Organs are at work testing heart-assist devices for adults and children.

This long-standing, successful program aims    –   this op-ed appeared on PennLive on May 11, 2016.  To continue reading click here:



Managing macular degeneration

When it comes to vision loss, macular degeneration poses the biggest threat.

People pay attention to cataracts, glaucoma and diabetic retinopathy…..

This article by Matthew Jojiri was published in the January 19, 2016 edition of the Reading Eagle.  Click here to continue reading:

Health care IT firm bolsters tech-related growth in downtown Harrisburg

It’s a lot like getting the band back together for a road trip.

That’s the way Mel Billingsley, president and CEO of the Harrisburg-based Life Sciences Greenhouse of Central Pennsylvania, describes a recent move by Maryland-based Evidera to open in the greenhouse’s building at 225 Market St.

This article appeared in the December 4th edition of the Central Penn Business Journal.  To continue reading click here:

First Ever Life Sciences Ecosystem Interactive Map Launched in Pennsylvania

Database of Companies Engaged in Life Sciences Now Available

PHILADELPHIA, PA—October 28 2015 —Ten technology and life science organizations in Pennsylvania announced the launch of an interactive “Life Sciences Ecosystem” map -­‐   a first of its kind database of life sciencesA cluster of scientific disciplines concerned with human life and health. Included are many branches of biology (e.g., molecular biology, cell biology) and chemistry (e.g., biochemistry), as well as some areas of genetics, physics and materials science, among others. organizations in Pennsylvania. The map highlights the diversity, breadth and scope of life sciences companies doing business in Pennsylvania. This comprehensive database includes therapeutic, medical technology, digital health and diagnostic companies, incubators, investors, research institutions, contract research organizations, and life sciences consultants. The map can be viewed at:

“Pennsylvania has a proud tradition of being a leader in the life sciences and this new map shows the diversity, complexity, and opportunity of the life sciences across the Commonwealth,” said Christopher P. Molineaux, President and CEO of Pennsylvania Bio. “As we position Pennsylvania as the hub of the life sciences in the United States, our first step is building a new awareness of our incredible community and its talents.”

Volunteers from the ten participating organizations worked for months to compile the data and refine it for placement on the interactive map. Users can search by company name, industry sector, and location. Companies that are new or not yet represented have an opportunity to add themselves to the map. The project was funded by BioAdvance, a Philadelphia based early stage investor, with the technical assistance of Bernard Lieberman.

“The map will be immensely valuable to anyone interested in locating their biotech business here in Pennsylvania, anyone looking for research facilities and services, and any company looking for partnerships or assistance as they grow,” said Barbara Schilberg, CEO of BioAdvance. “This is just the beginning; with the help of the rest of the Pennsylvania life sciences community, this tool will continue to expand and its value will continue to grow.”

The ten participating life sciences organizations are: BioAdvance, Pennsylvania Bio, University City Science Center, Montgomery County Development Authority, Pennsylvania Biotechnology Center of Bucks County, Pittsburgh Technology Council, Life Sciences Greenhouse of Central PA, Pittsburgh Life Sciences Greenhouse, Innovation Works, and the Greater Philadelphia Alliance for Capital and Technologies (PACT).

“Great advances in human health are happening every day in Pennsylvania,” added Schilberg, “Our life sciences companies are leading these innovations and at the same time creating jobs and growing communities. This map will help us tell that story.”

More information about each participating organization can be found on their websites:

Pennsylvania Bio
University City Science Center
Montgomery County Development Authority
Pennsylvania Biotechnology Center of Bucks County
Pittsburgh Technology Council
Life Sciences Greenhouse of Central PA
Pittsburgh Life Sciences Greenhouse Innovation Works
Greater Philadelphia Alliance for Capital and Technologies (PACT)

Contact: Barbara Schilberg, BioAdvance
Phone: 215-­‐966-­‐6214
Email: moc.e1487744505cnavd1487744505aoib@1487744505grebl1487744505ihcsb1487744505

Contact: Craig Tucker, Pennsylvania Bio
Phone: 484-­‐433-­‐1847
Email: gro.o1487744505ibap@1487744505rekcu1487744505tc1487744505

  • The Funding Process

    The Funding Process

    The Life Sciences Greenhouse of Central Pennsylvania provides investment funding up to $1 million in milestone-driven convertible…

    Read more
  • Our Resource Center


    It’s a familiar scenario. You hear about a discovery that could lead to the cure for this disease or that debilitating…

    Read more
  • The 'PA' in LSGPA


    The Life Sciences Greenhouse of Central Pennsylvania’s 42-county service area contains more than 60 institutions of higher …

    Read more